Mandecka Monika, Budziszewska Magdalena, Barczak Anna, Pepłońska Beata, Chodakowska-Żebrowska Małgorzata, Filipek-Gliszczyńska Anna, Nesteruk Marta, Styczyńska Maria, Barcikowska Maria, Gabryelewicz Tomasz
Department of Neurodegenerative Disorders, Mossakowski Medical Research Center, Polish Academy of Science, Warsaw, Poland.
Faculty of Psychology, University of Warsaw, Warsaw, Poland.
J Alzheimers Dis. 2016 Jul 29;54(1):157-68. doi: 10.3233/JAD-160176.
In the course of Alzheimer's disease (AD), early pathological changes in the brain start decades before any clinical manifestation. The concentration levels of AD cerebrospinal fluid (CSF) biomarkers, such as amyloid-β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau), may reflect a cerebral pathology facilitating an early diagnosis of the disease and predicting a cognitive deterioration. The aim of this study was to estimate the prevalence of AD CSF biomarkers in those individuals with a subjective cognitive decline (SCD), a mild cognitive impairment (MCI), and Alzheimer's dementia (AD-D), together with the relationships between the biomarkers, an APOE ɛ4 presence, and a verbal episodic memory performance. We included 252 patients from the memory clinic with a diagnosis of SCD (n = 85), MCI (n = 87), and AD-D (n = 80). A verbal episodic memory performance level was assessed and was based on a delayed recall trial from the 10-word list of an auditory verbal learning task (AVLT). We found that the patients with more severe cognitive impairments had significantly lower levels of Aβ1-42 and higher levels of T-tau and P-tau. This pattern was also typical for the APOE ɛ4 carriers, who had lower levels of Aβ1-42 than the noncarriers in the AD-D and MCI groups. The levels of T-tau and P-tau were significantly higher in the APOE ɛ4 carriers than in the noncarriers, but only in the MCI patients. The AVLT performance in the whole study samples was predicted by age, Aβ1-42, and the T-tau CSF biomarkers, but not by the APOE genotyping.
在阿尔茨海默病（AD）病程中，大脑的早期病理变化在出现任何临床表现的数十年前就已开始。AD脑脊液（CSF）生物标志物的浓度水平，如淀粉样β蛋白1-42（Aβ1-42）、总tau蛋白（T-tau）和磷酸化tau蛋白（P-tau），可能反映脑部病理状况，有助于疾病的早期诊断并预测认知功能衰退。本研究的目的是评估主观认知下降（SCD）、轻度认知障碍（MCI）和阿尔茨海默痴呆（AD-D）患者中AD CSF生物标志物的患病率，以及这些生物标志物、APOE ε4的存在与言语情景记忆表现之间的关系。我们纳入了记忆门诊的252例患者，诊断为SCD（n = 85）、MCI（n = 87）和AD-D（n = 80）。基于听觉言语学习任务（AVLT）10个单词列表的延迟回忆试验评估言语情景记忆表现水平。我们发现，认知障碍越严重的患者，Aβ1-42水平显著越低，T-tau和P-tau水平越高。这种模式在APOE ε4携带者中也很典型，在AD-D和MCI组中，他们的Aβ1-42水平低于非携带者。APOE ε4携带者的T-tau和P-tau水平显著高于非携带者，但仅在MCI患者中如此。整个研究样本中的AVLT表现可由年龄、Aβ1-42和T-tau CSF生物标志物预测，但不能由APOE基因分型预测。
